Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 8, 2010

IntegenX Wins DTRA Contract to Develop Pathogen Detection and Identification Platform

  • IntegenX has been awarded a contract by the Defense Threat Reduction Agency (DTRA) to develop an Integrated Sample-to-Sequence (ISS) system for rapid detection and identification of genetically engineered bacteria and viruses, medically relevant bacteria and viruses, and emerging pathogens. IntegenX will be the prime contractor for a first phase of $2.8 million and a possible 22-month, $14.8 million contract.

    IntegenX will use its Universal Sample Preparation Module, created under a previous DoD contract, to purify DNA from pathogen targets contained in complex matrices and present the purified material to an IntegenX library construction module, followed by an amplification module and a next-generation sequencing module. The company will apply its MOVe™ technology to integrate the complete workflow of the ISS system.

    “Our experience in next-generation sequencing library preparation and making a sample-to-answer system for forensic human identity testing has uniquely positioned IntegenX to accomplish the requirements that DTRA has requested,” comments Ezra van Gelder, evp of R&D. “IntegenX technology integrates the processes to incorporate the complex steps into a complete and straightforward sample-to-sequence workflow.”

    IntegenX, headquartered in Pleasanton, CA, designs, manufactures, and markets automated DNA- and RNA-based sample-preparation systems. The MOVe technology is a microfluidics platform that integrates advanced fluidics and analytical robotic capabilities to produce sample-to-answer performance for DNA and RNA sequencing, DNA-based forensics and human identity testing, biodefense, and molecular diagnostics applications. The company's first commercial platform, the Apollo 100™ System, is used to prepare DNA for sequencing.

    IntegenX says that its next release will be the Apollo 324 system to resolve the fragmented workflows in next-generation sequencing library preparation. IntegenX has successfully tested a sample-to-answer platform for human DNA identification, slated for commercialization in 2011.


Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »